Rare Disease Licensing Deal Benchmarks 2026

Rare disease licensing has become one of the most attractive segments in biopharma deal-making, driven by orphan drug exclusivity, accelerated regulatory pathways, and premium pricing. Phase 2 gene therapy deals for rare diseases carry a median total deal value of $4.5B, while enzyme replacement therapy deals reach $3.1B. Orphan drug designation provides 7 years of market exclusivity in the US and 10 years in the EU, underpinning strong deal economics.

Deal structures in rare disease reflect the unique commercial dynamics of small patient populations and high per-patient revenue. Development milestones average $815M for gene therapy approaches, with regulatory milestones of $926M rewarding the accelerated approval pathways frequently available to orphan drugs. Commercial milestones of $2.0B are structured around patient penetration rather than traditional revenue thresholds.

Royalty rates for rare disease licensing range from 8.7% to 17.4% at the base tier, reflecting the premium pricing power ($200K-$3M+ per patient annually for ERTs and gene therapies) and limited generic/biosimilar competition during the orphan exclusivity period. Assets with breakthrough therapy designation command additional premiums of 15-25% in deal terms.